Company profile: Ideaya Biosciences
1.1 - Company Overview
Company description
- Provider of oncology therapeutics for genetically defined cancers, with clinical-stage programs including darovasertib (IDE196) for GNAQ/GNA11-mutant tumors (metastatic uveal melanoma), IDE397 targeting MAT2A for MTAP-deleted tumors, and IDE161 for HRD tumors. Also offers synthetic lethality target identification with UCSD (CRISPR screens) and biomarker and translational research with the Broad Institute.
Products and services
- Darovasertib (IDE196): A clinical-stage development compound engineered for tumors harboring GNAQ or GNA11 mutations, focusing on metastatic uveal melanoma patient treatment
- IDE161: A clinical-stage development candidate created for tumors with homologous recombination deficiency (HRD), including specific breast and ovarian cancers
- IDE397: A clinical-stage development compound targeting MAT2A for patients with genetically-defined tumors having MTAP gene deletion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ideaya Biosciences
Maverick Therapeutics
HQ: United States
Website
- Description: Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maverick Therapeutics company profile →
Bright Peak Therapeutics
HQ: Switzerland
Website
- Description: Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bright Peak Therapeutics company profile →
Advaxis
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies for cancer and infectious diseases, based on a proprietary platform using live, attenuated bacteria engineered to secrete antigen/adjuvant fusion proteins to redirect the immune system to target and kill cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advaxis company profile →
TG Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for hematologic malignancies and autoimmune disorders, including BRIUMVI, a treatment for relapsing forms of multiple sclerosis—clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease—in adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TG Therapeutics company profile →
Acambis
HQ: United Kingdom
Website
- Description: Provider of vaccine research, development and manufacturing for the prevention and treatment of infectious diseases in Europe and North America, offering ACAM2000, a smallpox vaccine for emergency-use stockpiling, and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acambis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ideaya Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ideaya Biosciences
2.2 - Growth funds investing in similar companies to Ideaya Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ideaya Biosciences
4.2 - Public trading comparable groups for Ideaya Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →